Article
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Aug 2015
Iwata Kaori, Ryota Noriko, Hikita Ami, Sando Masumi, Suzuki Hidekazu, Tamiya Motohiro, Azuma Yuichiro, Tani Eriko, Hamaguchi Masanari, Tanaka Ayako, Shiroyama Takayuki, Morishita Naoko, Okamoto Norio, Futagami Sumiko, Hirashima Tomonori
Abstract excerpt
Afatinib is a newly approved second-generation epidermal growth factor receptor-tyrosine kinase inhibito r(EGFR-TKI). Afatinib has been shown to prolongthe overall survival of patients with non-small cell lungcancer (NSCLC) with EGFR mutations compared with the standard chemotherapy. However, Grade 3 or 4 toxicities, includingdiarrhea, rash, paronychia, and stomatitis, have been observed more frequently in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.